Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

SCRI Development Innovations

Status: Completed

Conditions: Metastatic Breast Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00876070

SCRI OUTCOMES 02

Details and patient eligibility

About

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

Enrollment: 198 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients that have received Abraxane chemotherapy greater than three months from the time of chart review.
• Patients that have received taxane chemotherapy greater than three months from the time of chart review.